CJC-1295 Research: Clinical Studies, Evidence & Scientific Review (2026)
From Peptidepedia, the trusted peptide wiki.
Medical Advisory Board
Research Evidence
The most significant clinical study on CJC-1295 was published in the Journal of Clinical Endocrinology & Metabolism in 2006. This randomized, placebo-controlled, double-blind trial examined pharmacokinetics, pharmacodynamics, and safety in healthy adults aged 21–61.
Key Findings:
Single injections produced dose-dependent increases in GH concentrations of 2- to 10-fold lasting 6 or more days
IGF-1 levels increased 1.5- to 3-fold for 9–11 days after a single dose
Multiple doses produced cumulative effects, with IGF-1 remaining elevated above baseline for up to 28 days
No serious adverse reactions were reported
The peptide was safe and relatively well tolerated, particularly at doses of 30 or 60 μg/kg
Animal Research: A study published in the American Journal of Physiology demonstrated that once-daily administration of CJC-1295 normalized growth in GH-deficient models, supporting its potential therapeutic applications.
Additional Study (2009): Research published in Growth Hormone & IGF Research further confirmed the activation of the GH/IGF-1 axis by CJC-1295, establishing its efficacy as a long-acting GHRH analog.
Important Note: A Phase II clinical trial investigating CJC-1295 for HIV-associated lipodystrophy was halted in 2006 following a patient death, though the relationship to the study drug was not definitively established.
This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.
References
Teichman SL, et al. Prolonged Stimulation of Growth Hormone (GH) and Insulin-Like Growth Factor I Secretion by CJC-1295, a Long-Acting Analog of GH-Releasing Hormone, in Healthy Adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805.
Jette L, et al. Human Growth Hormone-Releasing Factor (hGRF)1-29-Albumin Bioconjugates Activate the GRF Receptor on the Anterior Pituitary in Rats: Identification of CJC-1295 as a Long-Lasting GRF Analog. Endocrinology. 2005.
Alba M, et al. Once-daily administration of CJC-1295, a long-acting growth hormone-releasing hormone (GHRH) analog, normalizes growth in the GHRH knockout mouse. American Journal of Physiology-Endocrinology and Metabolism. 2006.
Ionescu M, Bhopale G. Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog. Growth Hormone & IGF Research. 2009.
Thomas A, et al. Identification of CJC-1295, a growth-hormone-releasing peptide, in an unknown pharmaceutical preparation. Drug Testing and Analysis. 2011.
Aidsmap. Lipodystrophy study halted after patient death. 2006.
World Anti-Doping Agency. The 2024 Prohibited List International Standard.
FDA. CJC-1295 - Pharmacy Compounding Advisory Committee Materials. December 2024.
Hone Health. Everything You Need to Know About the FDA Peptide Ban.
Innerbody. CJC-1295 + Ipamorelin: Benefits, Safety & Buying Advice.